Posted by Michael Wonder on 01 Oct 2015
1 October 2015 - Ceritinib (Zykadia) has been available since May 2015 for the treatment of adult patients with non small-cell ...
Read more →
Posted by Michael Wonder on 17 Sep 2015
15 September 2015 - Lomitapide (trade name: Lojuxta) has been available since July 2013 as additional treatment for adults with homozygous ...
Read more →
Posted by Michael Wonder on 16 Sep 2015
15 September 2015 - A 2011 German law designed to lower prices of new innovative drugs has not been as successful ...
Read more →
Posted by Michael Wonder on 15 Sep 2015
15 September 2015 - Lomitapide mesylate (trade name Lojuxta) has been approved since July 2013 for use by adults with homozygous ...
Read more →
Posted by Michael Wonder on 07 Sep 2015
7 September 2015 - Benefit assessments of medical interventions are conducted to answer the question: What is the benefit and possible ...
Read more →
Posted by Michael Wonder on 01 Sep 2015
1 September 2015 - Secukinumab (Cosentyx) was approved for use by adults with moderate to severe plaque psoriasis (psoriasis) in January ...
Read more →
Posted by Michael Wonder on 20 Aug 2015
17 August 2015 - Afatinib dimaleate (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients ...
Read more →
Posted by Michael Wonder on 19 Aug 2015
17 August 2015 - Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
The fixed-dose combination aclidinium bromide/formoterol has been approved since November 2014 for long-term treatment of adults with chronic obstructive pulmonary ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
[:content [\9 \space \F \e \b \r \u \a \r \y \space \2 \0 \1 \4 \space \- \T \h \e \space \G \e \r \m \a \n \space \F \e \d \e \r \a \l \space \J \o \i \n \t \space \C \o \m \m \i \t \t \e \e \space \( \G \- \B \A \) \, \space \t \h \e \space \d \e \c \i \s \i \o \n \- \m \a \k \i \n \g \space \b \o \d \y \space \o \f \space \t \h \e \space \s \e \l \f \- \g \o \v \e \r \n \i \n \g \space \h \e \a \l \t \h \c \a \r \e \space \s \y \s \t \e \m \space \i \n \ \G \e \r \m \a \n \y \, \space \r \e \c \e \n \t \l \y \space \c \o \n \f \i \r \m \e \d " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
Sucroferric oxyhydroxide (trade name Velphoro) has been approved since August 2014 for adults with chronic kidney disease on haemodialysis or ...
Read more →
Posted by Michael Wonder on 05 Aug 2015
[:content [\3 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \ \D \a \b \r \a \f \e \n \i \b \space \( \T \a \f \i \n \l \a \r \) \space \h \a \s \space \b \e \e \n \space \a \p \p \r \o \v \e \d \space \s \i \n \c \e \space \A \u \g \u \s \t \space \2 \0 \1 \3 \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t \space \o \f \space \a \d \v \a \n \c \e \d \space \m \e \l \a \n \o \m \a \. \space \I \n \space \J \a \n \u \a \r \y \space \2 \0 \1 \4 \, " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
[:content [\I \Q \W \i \G \space \h \a \s \space \f \o \u \n \d \space \t \h \a \t \space \S \t \r \i \b \i \l \d \ \h \a \s \space \a \space \\ \" \s \m \a \l \l \e \r \\ \" \space \b \e \n \e \f \i \t \space \t \h \a \n \space \t \h \e \space \c \o \m \p \a \r \a \t \o \r \space \A \t \r \i \p \l \a \ \w \h \e \n \space \u \s \e \d \space \t \o \ \t \r \e \a \t \space \H \I \V \- \1 \space \i \n \f \e \c \t \i \o \n \space \i \n \space \t \r \e \a \t \m \e \n \t \- \n \a \Ã \¯ \v \e \space \a \d \u \l \t \s \space \o \r " ..."]]
Read more →
Posted by Michael Wonder on 05 Aug 2015
Since November 2014 nintedanib (trade name: Vargatef) has been approved in combination with docetaxel for the treatment of adults with ...
Read more →